Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.

Journal: Cell

Published: 2020-05-14

DOI: 10.1016/j.cell.2020.04.020

Affiliations: 8

Authors: 15

Go to article
Institutions Share
Stanford University, United States of America (USA) 0.73
DNARx LLC, United States of America (USA) 0.13
Duke University Health System, United States of America (USA) 0.07
Los Altos High School (LAHS), United States of America (USA) 0.07

Return